In this report, marine-derived pharmaceuticals are described in terms of their history in medicine, technology types and categories, research organizations, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends.
Global Markets for Marine-Derived Pharmaceuticals Published:October 2011 No.Of pages:180 Price:US $ 4850 INTRODUCTION The search for bioactive metabolites from marine microbes has only just begun”—David Newman, D. Phil, and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide is Turning (2006) STUDY GOALS AND OBJECTIVES BCC’s goal in conducting this study was to determine the current status of the global marine-derived pharmaceutical market, including its growth potential during the period of 2011 to 2016. Our key objective is to present a comprehensive analysis of marine life and technology as they relate to pharmaceutical applications and to forecast this market’s future direction. REASONS FOR DOING THIS STUDY Our understanding of marine life only began during the last half of the 20th century. The first marine discovery that led to a pharmaceutical drug began in the 1950s when chemists Bergmann and Feeney isolated nucleosidic compounds from the Caribbean sponge Cryptotethya crypta. Marine drugs on the market today can be traced to this discovery (e.g., anticancer drug cytarabine). While marine life is used for many applications, including food and industrial processing, its use in the pharmaceutical industry has just begun. Marine life offers a complex and diverse genetic resource unavailable on land, which has led to the exploration of the oceans to find new tests and cures for illnesses. Entire classes of antibiotics desperately needed for a world surviving on relatively few antibiotics, which people are becoming resistant to, could be found in just a few marine samples. The report Global Markets for Marine-Derived Pharmaceuticals describes the potential of marine research and its growth prospects. It is estimated that marine-derived drugs will essentially double in number from 2011 to 2016. Because marine-derived drugs already account for a few powerful drugs, this area of the drug industry has already generated billions of dollars to date. SCOPE OF REPORT The scope of this study encompasses research organizations, the U.S. government chiefly in the form of the National Cancer Institute (NCI), and companies that develop or help in the development process of pharmaceuticals derived from marine life. Included are extensive descriptions, perspectives, and predictive information, including forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed. INTENDED AUDIENCE In this report, marine-derived pharmaceuticals are described in terms of their history in medicine, technology types and categories, research organizations, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This study will be of interest to non-profits and the government sector as well as the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested in or actively working in drug and imaging agent research and investors in all of the above. METHODOLOGY BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing the financial value of marine-derived pharmaceuticals. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company and government officials as well as experts in academia. INFORMATION SOURCES BCC’s analysis includes the review of more than 50 companies and information from financial and trade publications as well as the U.S. Food and Drug Administration (FDA). Included were pharmaceutical and biotechnology companies as well as support companies to them. ABOUT THE AUTHOR Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature. She acquired experience as a healthcare journalist, including working for John Wiley & Sons for years as a print reporter, before serving as a research analyst in a small market research firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area of North Carolina. Before joining that firm, Kim published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.| Table Of Contents Chapter- 1: INTRODUCTION - Complimentary STUDY GOALS AND OBJECTIVES REASONS FOR DOING THIS STUDY SCOPE OF REPORT INTENDED AUDIENCE METHODOLOGY INFORMATION SOURCES ABOUT THE AUTHOR RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMER Chapter- 2: EXECUTIVE SUMMARY INVESTMENT AND PATH FORWARD KEY DRIVERS KEY CHALLENGES KEY TRENDS INVESTMENT LANDSCAPE Chapter- 3: OVERVIEW HISTORY OF MARINE DRUGS MAJOR CATEGORIES OF MARINE DRUGS Chapter- 4: MARKET LANDSCAPE COMMERCIALIZED MARINE LIFE DRUGS BY TYPE PHARMACEUTICAL MARKET IN GENERAL MARINE-DERIVED DRUG LANDSCAPE COMMERCIALIZATION LANDSCAPE BY 2016 MECHANISMS OF ACTION MARINE DRUG CULTIVATION REGULATORY ENVIRONMENT PATENTS MARINE DRUG DEVELOPMENT: AREAS OF FOCUS TO WATCH MARINE DRUG DEVELOPMENT RESEARCH DISEASES/CONDITIONS MOST OFTEN TREATED WITH MARINE DRUGS Chapter- 5: COMPANY PROFILES ABBOTT LABORATORIES AFFIRIS AG AKER BIOMARINE ASA ALGENICS APHIOS CORP. APP PHARMACEUTICALS ARCTICZYMES ASKA PHARMACEUTICAL CO., LTD. ASTELLAS (AGENSYS, INC.) AQUAPHARM BIODISCOVERY, LTD. AZUR PHARMA BASF SE BAYER INNOVATION BEDFORD LABORATORIES BIOSYN CORP. BIOVEST INTERNATIONAL, INC. BTG INTERNATIONAL, LTD. CATABASIS PHARMACEUTICALS, INC. CELLDEX THERAPEUTICS CENTOCOR ORTHO BIOTECH COGNETIX, INC. COMENTIS CYANOTECH CORP. EISAI CO., LTD. ELAN CORP. (ELAN PHARMACEUTICALS, INC.) EUROPHARMA, INC. GENZYME GILEAD SCIENCES, INC. GLAXOSMITHKLINE GLYCOMAR, LTD. GILEAD SCIENCES HOSPIRA, INC. IMMUNOPHOTONICS INTEGRIN ADVANCED BIOSYSTEMS INTERMED DISCOVERY GMBH INTRACEL KLINIPHARM GMBH MAGELLAN BIOSCIENCE GROUP, INC MARINE POLYMER TECHNOLOGIES, INC. MARINOVA PTY, LTD. MARTEK BIOSCIENCES CORP. MEDIMETRIKS PHARMACEUTICALS MERA PHARMACEUTICALS MILLENNIUM, A TAKEDA ONCOLOGY CO. NAUTILUS BIOSCIENCES CANADA, INC. NÉOVACS NEUROBIOPHARM, INC. (PART OF NEPTUNE TECHNOLOGIES) NEREUS PHARMACEUTICALS OHR PHARMACEUTICALS PACIRA PHARMACEUTICALS, INC. PHARMAMAR PHARMA MARINE USA, LLC PHYCOSOURCE PML APPLICATIONS, LTD. PRIMEX EHF PROLUME, LTD. PRONOVA BIOPHARMA ASA SEA RUN HOLDINGS SEATTLE GENETICS, INC. SIGMA-TAU PHARMACEUTICALS, INC. STELLAR BIOTECHNOLOGIES STRATEGRO INTERNATIONAL, LLC TAIHO PHARMACEUTICALS TEQUESTA BIOVENTURES TRITON BIOPHARMA TRIUS THERAPEUTICS VERONA PHARMA, PLC XENOME, LTD. YAKULT HONSHA CO, LTD. ZELTIA GROUP (GRUPO ZELTIA) Chapter- 6: APPENDIX: RESOURCES Table 28 : MARINE RESEARCH RESOURCES BY CATEGORY Table 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRY List of Tables Summary Table : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS BY TYPE, THROUGH 2016 Table 1 : KEY DATES IN MARINE-DERIVED DRUG HISTORY Table 2 : GROWTH IN THE INTEREST IN MARINE NATURAL PRODUCTS BASED ON THE NUMBER OF PRODUCTS DESCRIBED IN SCIENTIFIC JOURNALS, 1999–2004 Table 3 : TOP 10 PHARMA IN SALES IN 2010 Table 4 : PHARMAMAR R&D PIPELINE IN THE U.S., 2011 Table 5 : MARINE-DERIVED DRUGS APPROVED AND IN LATE-STAGE DEVELOPMENT*, 2011 Table 6 : MARINE-DERIVED DRUGS/DRUG CANDIDATE’S MECHANISM OF ACTION Table 7 : KEY MARINE-DERIVED PRODUCT LIBRARIES Table 8 : KEY MARINE-DERIVED DRUG RESEARCH CANDIDATES: COMPOUNDS BY DRUG TYPE Table 9 : GLOBAL PHASE III PIPELINE FOR BREAST CANCER THROUGH 2016 Table 10 : GLOBAL PHASE III PIPELINE FOR BRAIN OR CNS CANCER, THROUGH 2016 Table 11 : GLOBAL PHASE III PIPELINE FOR BLADDER CANCER, THROUGH 2016 Table 12 : GLOBAL PHASE III PIPELINE FOR COLORECTAL CANCER, THROUGH 2016 Table 13 : GLOBAL PHASE III PIPELINE FOR HEAD AND NECK CANCER, THROUGH 2016 Table 14 : GLOBAL PHASE III PIPELINE FOR KIDNEY CANCER, THROUGH 2016 Table 15 : GLOBAL PHASE III PIPELINE FOR LEUKEMIA, THROUGH 2016 Table 16 : GLOBAL PHASE III PIPELINE FOR LIVER CANCER THROUGH 2016 Table 17 : GLOBAL PHASE III PIPELINE FOR LUNG CANCER THROUGH 2016 Table 18 : GLOBAL PHASE III PIPELINE FOR LYMPHOMA, THROUGH 2016 Table 19 : GLOBAL PHASE III PIPELINE FOR MULTIPLE MYELOMA, THROUGH 2016 Table 20 : GLOBAL PHASE III PIPELINE FOR OVARIAN CANCER, THROUGH 2016 Table 21 : GLOBAL PHASE III PIPELINE FOR PANCREATIC CANCER, THROUGH 2016 Table 22 : GLOBAL PHASE III PIPELINE FOR PROSTATE CANCER, THROUGH 2016 Table 23 : GLOBAL PHASE III PIPELINE FOR SARCOMA, THROUGH 2016 Table 24 : GLOBAL PHASE III PIPELINE FOR SKIN CANCER, THROUGH 2016 Table 25 : GLOBAL PHASE III PIPELINE FOR SOLID TUMORS, THROUGH 2016 Table 26 : GLOBAL PHASE III PIPELINE FOR STOMACH CANCER, THROUGH 2016 Table 27 : GLYCOMAR POLYSACCHARIDE CHARACTERIZATION SERVICES Table 28 : MARINE RESEARCH RESOURCES BY CATEGORY Table 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRY List of Figures Summary Figure : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS, 2010-2016 Figure 1 : THE TUNICATE ECTEINASCIDIA TURBINATE FROM WHICH YONDELIS (TRABECTEDIN) FOR CANCER TREATMENT IS MADE Figure 2 : MARINE SPECIES PER PHYLUM BASED ON WORMS Figure 3 : APPROXIMATION OF KNOWN VERSUS POSSIBLE SPECIES WITHIN THREE PHYLA, 2011 Figure 4 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2011 AND 2016 Figure 5 : COMMERCIALIZED MARINE DRUGS*, 2010–2016 Figure 6 : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS* BY THERAPEUTIC CATEGORY, 2009-2016 Figure 7 : COMMERCIALIZED MARINE DRUGS BY THERAPEUTIC AREA, 2011 Figure 8 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2016 Figure 9 : GLOBAL PHARMACEUTICAL DRUG SALES, 2010 Figure 10 : GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL SALES, 2010 AND 2016 Figure 11 : MARINE SAMPLE/MOLECULE CULTIVATION AND PROCESSING About Us: ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689 Contact: Mr.Priyank 7557 Rambler road, Suite727,Dallas,TX75231 Tel: + 1 888 391 5441 E-mail: firstname.lastname@example.org http://www.reportsnreports.com Visit our Market Research Blog
Pages to are hidden for
"Global Markets for Marine-Derived Pharmaceuticals"Please download to view full document